Document:

exv4w1

 

Exhibit 4.1

SUPPLEMENTAL INDENTURE

     THIS SUPPLEMENTAL INDENTURE (“Supplemental Indenture”), dated as of March 15, 2007, by and
among General Cable Corporation, a Delaware corporation (“General Cable” or the “Company”), the
Guarantors names on Schedule A hereto (collectively, the “Subsidiary Guarantors”) and U.S. Bank
National Association, as trustee (the “Trustee”).

RECITALS

     WHEREAS, the Company, certain of the Subsidiary Guarantors (the “Guarantors”) and the Trustee
have heretofore executed and delivered an Indenture, dated as of November 24, 2003 (the
“Indenture”), pursuant to which the Company issued $285,000,000 in aggregate principal amount of
its 9.50% Senior Notes due 2010 (the “Notes”); and

     WHEREAS, the Company and the Guarantors propose to amend the Indenture (the “Proposed
Amendments”), to remove substantially all of the restrictive covenants; and

     WHEREAS, the Company commenced a tender offer (the “Offer”) to purchase any and all of the
Notes pursuant to an Offer to Purchase and Consent Solicitation Statement dated as of March 6,
2007; and

     WHEREAS, in connection with the Offer, the Company solicited the consent of the holders of the
Notes for the Proposed Amendments; and

     WHEREAS, Section 8.02 of the Indenture provides that the Company, the Guarantors and the
Trustee may, with the written consent and direction of the holders of at least a majority in
aggregate principal amount of the outstanding Notes (the “Requisite Consent”) enter into a
supplemental indenture for the purpose of amending the Indenture; and

     WHEREAS, the Trustee has received the Requisite Consent to effect an amendment to the
Indenture pursuant to 8.02 of the Indenture and the documents described in Section 8.06 of the
Indenture; and

     WHEREAS, each of the Company and the Guarantors has been authorized by a resolution of its
respective Board of Directors to enter into this Supplemental Indenture; and

     WHEREAS, all other acts and proceedings required by law, by the Indenture and by the amended
and restated certificate of incorporation and amended and restated by-laws, or other governing
documents, of the Company and the Guarantors to make this Supplemental Indenture a valid and
binding agreement for the purposes expressed herein, in accordance with its terms, have been duly
done and performed; and

     WHEREAS, the Trustee is authorized to execute and deliver this Supplemental Indenture; and

     WHEREAS, following the execution and delivery of this Supplemental Indenture, the Proposed
Amendments will become operative on the date (the “Operative Date”) on which the Company accepts
for purchase Notes validly tendered, and not withdrawn in the Offer (the “Tender Offer Condition”);
and

A-1

 

     WHEREAS, the terms of this Supplemental Indenture shall be null and void, and of no further
force or effect, and the Proposed Amendments shall not become operative if the Tender Offer
Condition does not occur.

     NOW, THEREFORE, in consideration of the premises and the covenants and agreements contained
herein, and for other good and valuable consideration the receipt of which is hereby acknowledged,
and for the equal and proportionate benefit of the holders of the Notes, the Company, the
Subsidiary Guarantors and the Trustee, intending to be legally bound, hereby agree as follows:

ARTICLE ONE

Section 1.01 Definitions.

     Capitalized terms used in this Supplemental Indenture and not otherwise defined herein shall
have the meanings assigned to such terms in the Indenture.

ARTICLE TWO

Section 2.01 Amendment of Indenture

     Effective as of the Operative Date, this Supplemental Indenture amends the Indenture as
provided for herein. The Company, the Guarantors and the Trustee acknowledge and agree that no
amendment or waiver of the provisions described in Section 8.02 (1) through (2) of the Indenture as
requiring the consent of each affected Holder has been made hereby. If the Operative Date does not
occur on or prior to the date that is sixty (60) days following the date of this Supplemental
Indenture, then the terms of this Supplemental Indenture shall be null and void and the Indenture
shall continue in full force and effect without any modification hereby.

Section 2.02 Amendment of Article Four of the Indenture

     Pursuant to Section 8.02 of the Indenture, the provisions of Article Four of the Indenture are
hereby amended as follows:

     (a) the covenant contained in Section 4.03 of the Indenture entitled “Legal Existence” is
amended in its entirety to read as follows:

          Section 4.03 [Intentionally Omitted]

     (b) the covenant contained in Section 4.04 of the Indenture entitled “Maintenance of
Properties; Insurance; Compliance with Law” is amended in its entirety to read as follows:

          Section 4.04 [Intentionally Omitted]

     (c) the covenant contained in Section 4.06 of the Indenture entitled “Compliance Certificate”
is amended in its entirety to read as follows:

          Section 4.06 [Intentionally Omitted]

     (d) the covenant contained in Section 4.07 of the Indenture entitled “Taxes” is amended in its
entirety to read as follows:

A-2

 

          Section 4.07 [Intentionally Omitted]

     (e) the covenant contained in Section 4.08 of the Indenture entitled “Repurchase at the Option
of Holders upon a Change in Control” is amended in its entirety to read as follows:

          Section 4.08 [Intentionally Omitted]

     (f) the covenant contained in Section 4.09 of the Indenture entitled “Limitation on Restricted
Payments” is amended in its entirety to read as follows:

          Section 4.09 [Intentionally Omitted]

     (g) the covenant contained in Section 4.10 of the Indenture entitled “Limitation on
Indebtedness and Issuance of Disqualified Capital Stock” is amended in its entirety to read as
follows:

“(a) [Intentionally Omitted]

(b) [Intentionally Omitted]

(c) [Intentionally Omitted]

(d) Section 4.10. None of the Company or
any Guarantor shall, directly or indirectly, Incur
any Indebtedness that by its terms (or by the terms
of any agreement governing such Indebtedness) would
be expressly subordinate or junior in right of
payment in any respect to any other Indebtedness
unless such Indebtedness is also by its terms (or by
terms of any agreement governing such Indebtedness)
subordinate or junior in right of payment to the
Notes or the Guarantees, as applicable, at least to
the same extent such Indebtedness is subordinated or
junior in right of payment to such other
Indebtedness.”

     (h) the covenant contained in Section 4.11 of the Indenture entitled “Limitation on Sales of
Assets” is amended in its entirety to read as follows:

          Section 4.11 [Intentionally Omitted]

     (i) the covenant contained in Section 4.12 of the Indenture entitled “Limitation on Dividend
and Other Payment Restrictions Affecting Subsidiaries” is amended in its entirety to read as
follows:

          Section 4.12 [Intentionally Omitted]

A-3

 

     (j) the covenant contained in Section 4.13 of the Indenture entitled “Limitation on
Transactions with Affiliates” is amended in its entirety to read as follows:

          Section 4.13 [Intentionally Omitted]

     (k) the covenant contained in Section 4.14 of the Indenture entitled “Limitation on
Designations of Unrestricted Subsidiaries” is amended in its entirety to read as follows:

          Section 4.14 [Intentionally Omitted]

     (l) the covenant contained in Section 4.15 of the Indenture entitled “Limitation on Liens” is
amended in its entirety to read as follows:

          Section 4.15 [Intentionally Omitted]

     (m) the covenant contained in Section 4.16 of the Indenture entitled “Limitations on
Sale/Leaseback Transactions” is amended in its entirety read as follows:

          Section 4.16 [Intentionally Omitted]

     (n) the covenant contained in Section 4.17 of the Indenture entitled “Subsidiary Guarantees”
is amended in its entirety to read as follows:

          Section 4.17 [Intentionally Omitted]

     (o) the covenant contained in Section 4.18 entitled “Provisions of Financial Information” is
amended in its entirety to read as follows:

          Section 4.18 [Intentionally Omitted]

     (p) the covenant contained in Section 4.19 of the Indenture entitled “Limitation on Capital
Stock of Restricted Subsidiaries” is amended in its entirety to read as follows:

          Section 4.19 [Intentionally Omitted]

ARTICLE THREE

Section 3.01 Privileges and Immunities of Trustee.

     The Trustee accepts the amendment of the Indenture effected by this Supplemental Indenture but
only upon the terms and conditions set forth in the Indenture, including the terms and provisions
defining and limiting the liabilities and responsibilities of Trustee, which terms and provisions
shall in like manner define and limit its liabilities and responsibilities in the performance of
the trust created by the Indenture as hereby amended. The Trustee shall not be responsible for the
adequacy or sufficiency of the Supplemental Indenture, for the due execution thereof by the Company
and the Guarantors or for the recitals contained herein, which are the Company’s and the
Guarantors’ responsibilities.

A-4

 

ARTICLE FOUR

Section 4.01 Effectiveness of the Supplemental Indenture.

     The provisions of this Supplemental Indenture will take effect immediately upon execution and
delivery thereof by the parties hereto provided that the Proposed Amendments become operative on
the Operative Date of this Supplemental Indenture. If the Tender Offer Condition does not occur,
the terms of this Supplemental Indenture shall be null and void.

Section 4.02 Continuing Effect of Indenture.

     Except as expressly provided herein, all of the terms, provisions and conditions of the
Indenture and the Notes outstanding thereunder shall remain in full force and effect.

Section 4.03 Construction of Supplemental Indenture.

     This Supplemental Indenture is executed as and shall constitute an indenture supplemental to
the Indenture and shall be construed in connection with and as part of the Indenture. This
Supplemental Indenture shall be governed by and construed in accordance with the laws of the State
of New York.

Section 4.04 Trust Indenture Act Controls.

     If any provision of this Supplemental Indenture limits, qualifies or conflicts with another
provision of this Supplemental Indenture or the Indenture that is required to be included by the
Trust Indenture Act of 1939, as amended, as in force at the date this Supplemental Indenture is
executed, the provision required by said Act shall control.

Section 4.05 Trustee Disclaimer.

     The recitals contained in this Supplemental Indenture shall be taken as the statements of the
Company and the Guarantors, and the Trustee assumes no responsibility for their correctness. The
Trustee makes no representations as to the validity or sufficiency of this Supplemental Indenture.

Section 4.06 Counterparts.

     This Supplemental Indenture may be executed in any number of counterparts, each of which so
executed shall be deemed to be an original, but all such counterparts shall together constitute but
one and the same instrument.

[SIGNATURES ON NEXT PAGE]

A-5

 

     IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed as of the day and year first above written.

	 	 	 	 	 
	 	GENERAL CABLE CORPORATION

 	 
	 	By:  	/s/ Robert J. Siverd
 	 
	 	 	Name:  	Robert J. Siverd 	 
	 	 	Title:  	Executive Vice President,

General Counsel and Secretary 	 
	 
	 	GENCA CORPORATION

GENERAL CABLE INDUSTRIES, INC.

GENERAL CABLE INDUSTRIES LLC

GENERAL CABLE MANAGEMENT LLC

GENERAL CABLE OVERSEAS HOLDINGS, INC.

GENERAL CABLE TECHNOLOGIES CORPORATION

GENERAL CABLE TEXAS OPERATIONS L.P.

GK TECHNOLOGIES, INCORPORATED

DIVERSIFIED CONTRACTORS, INC.

MARATHON MANUFACTURING HOLDINGS, INC.

MARATHON STEEL COMPANY

MLTC COMPANY

 	 
	 	By:  	/s/ Robert J. Siverd
 	 
	 	 	Name:  	Robert J. Siverd 	 
	 	 	Title:  	Executive Vice President,

General Counsel and Secretary 	 
	 
	 	U.S. BANK NATIONAL ASSOCIATION,

as Trustee

 	 
	 	By:  	/s/ Robert T. Jones
 	 
	 	 	Name:  	Robert T. Jones 	 
	 	 	Title:  	Vice President 	 

A-6

 

	 	 	 	 	 

SCHEDULE “A”

SUBSIDIARY GUARANTORS

GENCA CORPORATION

GENERAL CABLE INDUSTRIES, INC.

GENERAL CABLE INDUSTRIES LLC

GENERAL CABLE MANAGEMENT LLC

GENERAL CABLE OVERSEAS HOLDINGS, INC.

GENERAL CABLE TECHNOLOGIES CORPORATION

GENERAL CABLE TEXAS OPERATIONS L.P.

GK TECHNOLOGIES, INCORPORATED

DIVERSIFIED CONTRACTORS, INC.

MARATHON MANUFACTURING HOLDINGS, INC.

MARATHON STEEL COMPANY

MLTC COMPANY

A-1exv10w41

 

Exhibit 10.41

Portions of this exhibit were omitted and filed separately with the Secretary of the
Commission pursuant to an application for confidential treatment filed with the Commission pursuant
to Rule 24b-2 under the Securities Exchange Act of 1934. Such portions are marked by a series of
asterisks.

Amendment Number 1

to Research, Co-Development 

and Commercialization Agreement and Research License and Option

Agreement

     This Amendment Number 1 (the “Amendment”) to the Collaboration Agreement and the
License Agreement (both as defined below) is effective as of
October 20, 2006 (the “Effective
Date”), and is by and between BioGeneriX AG, a corporation organized under the laws of the Federal
Republic of Germany (“BioGeneriX”), and Neose Technologies, Inc., a corporation organized and
existing under the laws of the state of Delaware (“Neose”).

Background

     BioGeneriX and Neose entered into a Research, Co-Development and Commercialization Agreement
dated April 20, 2004 (the “Collaboration Agreement”), pursuant to which BioGeneriX and Neose are
collaborating to develop a next-generation G-CSF. BioGeneriX and Neose entered into a Research,
License and Option Agreement dated April 27, 2005 (the “License Agreement”), pursuant to which
BioGeneriX has the option to license certain technology for the development and commercialization
of an undisclosed protein. The Collaboration Agreement and the License Agreement are sometimes
referred to collectively as the “Agreements.”

     Neose and BioGeneriX desire to amend both Agreements as set forth herein. All capitalized
terms used in this Amendment and not otherwise defined shall have the meanings set forth in the
Collaboration Agreement, unless otherwise indicated.

Terms

     Now, therefore, intending to be legally bound, the parties hereto agree as follows:

1. Extension of BioGeneriX Decision Date.

     1.1. Section 1.4. Section 1.4 of the Collaboration Agreement is hereby amended and
restated in full to read as follows:

“BioGeneriX Decision Date” means December 31, 2006.

     1.2. Section 24.2. Section 24.2 of the Collaboration Agreement is hereby amended by
deleting the first sentence and replacing it with the following:

 

			
	******	 	— Material has been omitted and filed separately with the Commission.

 

 

          “This Agreement may be terminated by BioGeneriX by written notice to Neose on
the BioGeneriX Decision Date.”

     1.3. Section 24.4.2. Section 24.4.2 of the Collaboration Agreement is hereby deleted.

2. Extension of Option Expiration Date. Section 1.30 of the License Agreement is hereby
amended and restated in full to read as follows:

          “1.30. “Option Expiration Date” means December 31, 2006.”

3. Diligence Requirements.

     3.1. Termination by Neose. Neose shall have the right to terminate either or both of
the Collaboration Agreement and the License Agreement (provided that the License Agreement may be
so terminated only if the Option, as defined therein, has not been exercised in accordance with the
License Agreement), effective immediately upon notice to BioGeneriX, if any of the events listed in
Section 3.1.1 through Section 3.1.6 occurs. In the event Neose terminates the Collaboration
Agreement, Neose shall, at its election and upon written notice to BioGeneriX, be a “Continuing
Licensee” for purposes of Section 24 of the Collaboration Agreement, with the rights and
obligations set forth therein.

            3.1.1. The first patient in the first Phase I clinical trial is not dosed on or before the
earlier of (i) the 30th day following ****** approval and (ii) December 31, 2006.

            3.1.2. The first ******.

            3.1.3. The safety ******.

            3.1.4. The ******.

            3.1.5. A full and complete ******.

            3.1.6. The first ******.

     3.2. Effect of Termination. If the Agreement is terminated for any reason, including
without limitation a termination by Neose pursuant to Section 3.1 of this Amendment or by
BioGeneriX on the BioGeneriX Decision Date, the diligence requirements listed in Section 3.1 and
BioGeneriX’s obligation in Section 4 of this Amendment will terminate effective upon such
termination.

     3.3. Effect of Failure to Meet Diligence Requirements. The failure of BioGeneriX to
meet any diligence requirement will not constitute a breach of the Agreement.

 

			
	******	 	— Material has been omitted and filed separately with the Commission.

-2-

 

     3.4. Effect of Delay in Process Reagents. If a diligence requirement is missed
because of the failure of Neose to supply reasonable quantities of process reagents of appropriate
quality as described below:

	 	 	 	 	 
	Reagent	 	Supplier	 	Quality
	******

	 	******
	 	******
	******

	 	******
	 	******
	******

	 	******
	 	******
	******

	 	******
	 	******

the date for completion of the diligence requirement will be extended by the amount of the delay
caused by the delay in delivery.

4. Cost of Process Reagents. From and after January 1, 2007, BioGeneriX will pay for the
cost of the process reagents to be supplied by Neose pursuant to Section 6.2.4 of the Collaboration
Agreement. For the purpose of this Section 4, “cost” shall mean ******

5. Sharing of Information. With respect to Next-Generation G-CSF, BioGeneriX will provide
to Neose copies of (i) all preclinical data and reports not already provided to Neose within 10
days after receipt; (ii) all clinical data, including all raw data and data tables, and reports
within 10 days after receipt at BioGeneriX, ******, whichever occurs first; (iii) all written
correspondence and minutes of oral communications with regulatory authorities; (iv) serious adverse
event reports either within 2 working days after receipt at BioGeneriX, or simultaneous with notice
to BioGeneriX by ******, whichever occurs first; and (v) copies of all regulatory authority
correspondence from BioGeneriX, ****** within 5 working days after submission.

6. Confirmation of Preclinical Development Completion Date. With respect to
Next-Generation G-CSF Neose and BioGeneriX agree that Preclinical Development shall have been
completed as of ******.

7. Notices. Any notice, consent or report (each, a “Notice”) required or permitted to be
given by either Party under this Agreement shall be in writing and shall be either personally
delivered or sent by facsimile (confirmed by internationally-recognized express courier), or by
internationally-recognized express courier (such as Federal Express or DHL), to the other Party at
its address set forth below, or such new address as may from time to time be supplied under this
Agreement by a Party. Except as otherwise set forth in this Agreement, any Notice shall be
effective upon receipt by the addressee. Provided that all postage or delivery charges are prepaid
in full by the sender and the Notice has been addressed as set forth in this Agreement:

     7.1. if such Notice is sent by facsimile (confirmed by internationally recognized express
courier, which confirmation includes a copy of the report showing the

 

			
	******	 	— Material has been omitted and filed separately with the Commission.

-3-

 

date and time of transmission), then the Notice shall be deemed to be received upon
transmission (if transmitted on a business day) or the next business day following transmission;
and

     7.2. if such Notice is personally delivered or sent by internationally-recognized express
courier, then the Notice shall be deemed to be received three business days after deposit with the
courier service.

 

			
	******	 	— Material has been omitted and filed separately with the Commission.

-4-

 

	 	 	 
	If to BioGeneriX:

	 	BioGeneriX AG
	 

	 	High-Tech-Park Neckarau
	 

	 	Janderstrasse 3
	 

	 	D-68199 Mannheim
	 

	 	Germany
	 

	 	Attention: Chief Financial Officer
	 
	 	 
	If to Neose:

	 	Neose Technologies, Inc.
	 

	 	102 Witmer Road
	 

	 	Horsham, PA 19044
	 

	 	USA
	 

	 	Attention: General Counsel

8. No Other Changes. Except as expressly modified in this Amendment or as is inconsistent
with the terms of this Amendment, the Collaboration Agreement and License Agreement shall remain
unchanged and in full force and effect.

9. Counterparts. This Amendment may be executed in one or more counterparts, each of which shall
be an original and all of which, together, shall constitute the same document.

[signature page follows]

 

			
	******	 	— Material has been omitted and filed separately with the Commission.

-5-

 

          In witness whereof, the parties have executed this Amendment as of the Effective
Date.

	 	 	 	 	 	 	 
	 	 	Neose Technologies, Inc.
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ George J. Vergis	 	 
	 

	 	 	 	George J. Vergis, Ph.D.	 	 
	 

	 	 	 	President and Chief Executive Officer	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	BioGeneriX AG
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Elmar Schäfer	 	 
	 

	 	 	 	Name: Elmar Schäfer	 	 
	 

	 	 	 	Title: CEO	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Klaus Maleck	 	 
	 

	 	 	 	Name: Dr. Klaus Maleck, MBA	 	 
	 

	 	 	 	Title: CFO and Vice President Bus. Dev.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]